Targeting androgen receptors in advanced prostate cancer
Targeting AR and AR-Variants in Castration-Resistant Prostate Cancer
This study is looking for new ways to treat castration-resistant prostate cancer by targeting specific parts of the cancer cells that help them grow, and it’s for anyone dealing with this tough condition, especially since some current treatments aren’t working as well as hoped.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Texas A&m University Health Science Ctr NIH-funded |
| Lab location | 1 site (College Station, United States) |
| Project ID | NIH-11014414 on NIH RePORTER |
What this research studies
This research focuses on developing new treatments for castration-resistant prostate cancer (CRPC) by targeting androgen receptors (AR) and their variants. Current therapies often fail due to the emergence of AR-splice variants that allow cancer to grow despite treatment. The researchers aim to create small molecules that can inhibit AR expression or promote its degradation, potentially leading to more effective therapies. Preliminary studies have shown that a compound called Urolithin A can inhibit AR signaling and suppress the growth of AR-positive CRPC, and the team plans to develop more potent analogs of this compound.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with castration-resistant prostate cancer who have not responded to conventional androgen deprivation therapies.
Not a fit: Patients with early-stage prostate cancer or those who have not yet undergone androgen deprivation therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with advanced prostate cancer that no longer respond to standard therapies.
How similar studies have performed: Other research has shown promise in targeting androgen receptors in prostate cancer, but this approach using Urolithin A analogs is relatively novel.
Where this research is happening
College Station, United States
- Texas A&m University Health Science Ctr — College Station, United States (Active)
Researchers
- Principal investigator: Damodaran, Chendil — Texas A&m University Health Science Ctr
- Study coordinator: Damodaran, Chendil
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.